Ex vivo expansion of transplantable human hematopoietic stem cells: where do we stand in the year 2000?
Ex vivo expansion of transplantable human hematopoietic stem cells: where do we stand in the year 2000?
复制标题
可移植人类造血干细胞的离体扩增：2000 年我们处于什么位置？
DOI：
10.1089/15258160050196650
复制
发表时间：
2000
期刊：
影响因子：
--
通讯作者：
Forman,SJ
中科院分区：
文献类型：
--
作者：
Shih,CC;DiGiusto,D;Forman,SJ
造血前体细胞、祖细胞和干细胞的离体扩增代表了 21 世纪细胞治疗的现代时代。在过去的十年中，识别和纯化造血干细胞和细胞因子的手段不断增加，促进和改进了离体干细胞扩增技术的发展。然而，技术尚未达到可以常规使用离体扩增的造血祖细胞和干细胞进行替代治疗的阶段。过去 10 年，从专注于开发最佳离体干细胞扩增系统的研究中汲取的经验教训，使人们对干细胞生物学有了更深入的了解。这些知识导致了造血前体细胞、祖细胞和干细胞的离体扩增的新尝试，并且应该促进新一代细胞疗法的开发。这篇综述讨论了临床上有用的干细胞扩增方案开发的最新进展。此外，我们还讨论了有限数量的临床试验的结果，这些临床试验探讨了此类手术的功效。讨论了影响临床可行性的离体干细胞扩增的三个主要领域，包括：（1）选择用于扩增的最佳干细胞群，（2）定义用于植入的扩增干细胞群的所需特征，以及（3）开发用于扩增和输注造血祖细胞和干细胞的新试剂和程序。
Ex vivo expansion of hematopoietic precursors, progenitors and stem cells represents the modern era of cellular therapeutics in the 21stcentury. For the last 10 years, increasing means for identifying and purifying hematopoietic stem cells and cytokines have facilitated and improved the development of ex vivo stem cell expansion technology. However, technology has not yet reached a stage where ex vivo-expanded hematopoietic progenitors and stem cells can be used routinely for replacement therapy. Lessons learned over the past 10 years from investigations focused at developing optimal ex vivo stem cell expansion systems have continued to a much greater understanding of stem cell biology. This knowledge has led to novel attempts at ex vivo expansion of hematopoietic precursors, progenitors, and stem cells, and should facilitate development of a new generation of cellular therapeutics. This review addresses recent progress toward development of clinically useful protocols for stem cell expansion. In addition, we discuss the results of a limited number of clinical trials that address the efficacy of such procedures. Three major areas of ex vivo stem cell expansion that impact clinical feasibility are discussed, including: (1) selection of an optimal stem cell population for expansion, (2) definition of the desired characteristics of the expanded stem cell population to be used for engraftment, and (3) development of new reagents and procedures for expansion and infusion of hematopoietic progenitors and stem cells.